Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05681234

Enrollment

Registered

2023-01-12

Start date

2022-08-24

Completion date

2022-12-20

Last updated

2023-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Carcinoma

Brief summary

This is a single arm study to evaluate the safety and biodistribution of 18F-labeled RD2 PET/CT Imaging in patients with small liver carcinoma.

Interventions

RADIATION18F-RD2

Patients will receive 5-10 mCi 18F-RD2

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients with highly suspected tumor； 2. Patients underwent PET/CT examination within 1 week; 3. Patients voluntarily signed informed consent; 4. Over 18 years old, male or female.

Exclusion criteria

1. Pregnant women; 2. Lactating women; 3. Patients with impaired renal function.

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of tissue distribution of 18F-RD2	2 hours	Biodistribution of 18F-RD2 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 18F-RD2 scans will be reported.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026